Douglas Grossman
( out of 462 reviews )

Douglas Grossman, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2C, Dermatology/Melanoma
1950 Circle of Hope
Salt Lake City , UT 84112
801-581-2955
Get Directions

Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004.

Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma.

Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.

Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.

Specialties

Board Certification

American Board of Dermatology (Dermatology)

Patient Rating

4.9 /5
( out of 462 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Dr Grossman is an expert, I completely trust him, his bedside manner is second to none, his knowledge and expertise are commendable.

HUNTSMAN CANCER CENTER

Dr. Grossman is easy to talk to. He handles his schedule in a timely manner and he is very thorough.

HUNTSMAN CANCER CENTER

Dr. Grossman is thorough in the exam, courteous and asks and listens to the patient. I am impressed with his attention to detsil.

HUNTSMAN CANCER CENTER

Dr. Grossman was punctual, polite, and informative. He listened carefully to my family history of melanoma, pointed out a few troubling moles, and asked if I had any questions. I would not hesitate to recommend him to anyone.

HUNTSMAN CANCER CENTER

Dr. Grossman is great. Always has my best interest in mind and is attentive to me during our visit.

HUNTSMAN CANCER CENTER

excellent

HUNTSMAN CANCER CENTER

Dr Grossman, supported by his team, was wholly focused on me and my care. The overview and updates as the procedure progressed were timely and easy to understand

HUNTSMAN CANCER CENTER

very informative

HUNTSMAN CANCER CENTER

Dr. Grossman showed a real interest in my care. He reviewed past visits and talked about a plan moving forward.

Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004.

Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma.

Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.

Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.

Board Certification and Academic Information

Academic Departments Dermatology -Professor
Board Certification
American Board of Dermatology (Dermatology)

Education history

Undergraduate Chemistry - Duke University B.S.
Doctoral Training Immunology; Laboratory of Robert R. Rich, M.D - Baylor College of Medicine Ph.D.
Professional Medical Medicine - Baylor College of Medicine M.D.
Internship Internal Medicine - Yale New Haven Hospital Intern
Residency Dermatology - Yale University School of Medicine Resident
Fellowship Laboratory of Dario C. Altieri, M.D. - Yale University School of Medicine Fellow

Selected Publications

Journal Article

  1. Bowen AR, Hanks AN, Murphy KJ, Florell SR, Grossman D (2004). Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol, 26(3), 177-81.
  2. McKenzie JA, Grossman D (2012). Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res, 32(2), 397-404.
  3. Grossman D, Leffell DJ (1997). The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol, 133(10), 1263-70.
  4. Liu J, Epand RF, Durrant D, Grossman D, Chi NW, Epand RM, Lee RM (2008). Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry, 47(15), 4518-29.
  5. Liu J, Epand R, Durrant D, Grossman D, Epand R, Lee R (2008). Regulation of tBid-induced apoptosis by mitochondrial phospholipid scramblase 3. Biochemistry, 47(4518), 4529.
  6. Wu YP, Kohlmann W, Curtin K, Yu Z, Hanson HA, Hashibe M, Parsons BG, Wong J, Schiffman JD, Grossman D, Leachman SA (2018). Melanoma risk assessment based on relatives' age at diagnosis. Cancer Causes Control, 29(2), 193-199.
  7. Nagelhout ES, Parsons BG, Haaland B, Tercyak KP, Zaugg K, Zhu A, Harding G, Yancey J, Jensen JD, Grossman D, Wetter DW, Wu YP (2019). Differences in reported sun protection practices, skin cancer knowledge, and perceived risk for skin cancer between rural and urban high school students. Cancer Causes Control, 30(11), 1251-1258.
  8. Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M (1995). Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood, 86(2), 651-8.
  9. LaBarbera DV, Modzelewska K, Glazar AI, Gray PD, Kaur M, Liu T, Grossman D, Harper MK, Kuwada SK, Moghal N, Ireland CM (2009). The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs, 20(6), 425-36.
  10. Wu YP, Aspinwall LG, Nagelhout E, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Cassidy P, Leachman SA (2018). Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ, 33(4), 774-781.
  11. Parsons BG, Hay JL, Aspinwall LG, Zaugg K, Zhu A, Mooney RH, Klein SZ, Grossman D, Leachman SA, Wu YP (2020). Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control. J Cancer Educ, 35(3), 509-514.
  12. Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U (2014). Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol, 171(5), 1099-107.
  13. Goodson AG, Varedi A, Hull C, Grossman D (2015). A safe and efficient model for ultraviolet radiation-induced herpes simplex labialis. Photodermatol Photoimmunol Photomed, 31(3), 170-2.
  14. Yan H, Brouha B, Liu T, Raj D, Biddle D, Lee R, Grossman D (2006). Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci, 43(3), 189-200.
  15. John KK, Jensen JD, King AJ, Pokharel M, Grossman D (2018). Emerging applications of eye-tracking technology in dermatology.(Epub ahead of print). J Dermatol Sci.
  16. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.
  17. Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW (2017). Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res, 27(6), 545-557.
  18. Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL (2020). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Melanoma Res, 30(2), 173-178.
  19. Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman D (2020). Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma Res, 30(3), 247-251.
  20. Grossman D, Altieri D (2001). Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer metastasis reviews, 20(1-2), 3-11.
  21. Zhang W, Hanks AN, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman (2005). UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis, 26(1), 249-57.
  22. Raj D, Liu T, Samadashwily G, Li F, Grossman (2008). Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis, 29(1), 194-201.
  23. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman (2013). Survivin promotion of melanoma metastasis requires upregulation of ¿5 integrin. Carcinogenesis, 34(9), 2137-44.
  24. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy P (2019). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44.
  25. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman (2003). Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer research, 63(3), 567-72.
  26. Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN, Grossman (2007). Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer research, 67(11), 5172-8.
  27. McKenzie JA, Liu T, Goodson AG, Grossman (2010). Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer research, 70(20), 7927-37.
  28. King AJ, Carcioppolo N, Grossman D, John KK, Jensen J (2015). A randomised test of printed educational materials about melanoma detection: Varying skin self-examination technique and visual image dose. Health education journal, 74, 732-42.
  29. Grossman D, Lamphear JG, Mollick JA, Betley MJ, Rich R (1992). Dual roles for class II major histocompatibility complex molecules in staphylococcal enterotoxin-induced cytokine production and in vivo toxicity. Infection and immunity, 60(12), 5190-6.
  30. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley M (1993). Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins. Infection and immunity, 61(8), 3175-83.
  31. He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee R (2007). Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. Journal of cellular biochemistry, 101(5), 1210-21.
  32. Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium (2019). Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Journal of clinical immunology, 39(7), 653-667.
  33. Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich R (1993). A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. The Journal of clinical investigation, 92(2), 710-9.
  34. Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri D (2001). Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. The Journal of clinical investigation, 108(7), 991-9.
  35. Parsons BG, Gren LH, Simonsen SE, Harding G, Grossman D, Wu Y (2018). Opportunities for Skin Cancer Prevention Education among Individuals Attending a Community Skin Cancer Screening in a High-Risk Catchment Area. Journal of community health, 43(2), 212-219.
  36. Wu YP, Parsons BG, Mooney R, Aspinwall LG, Cloyes K, Hay JL, Kohlmann W, Grossman D, Leachman S (2018). Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. Journal of community health, 43(5), 993-1001.
  37. Nagelhout ES, Lensink R, Zhu A, Parsons BG, Haaland B, Hashibe M, Grossman D, VanDerslice J, Gren LH, Jensen JD, Wu Y (2021). Higher Ultraviolet Radiation Exposure Among Rural-Dwelling Versus Urban-Dwelling Adults and Children: Implications for Skin Cancer Prevention. Journal of community health, 46(1), 147-155.
  38. Grossman D, Lewis DE, Ballas ZK, Duvic (1994). Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides. Journal of the American Academy of Dermatology, 31(2 Pt 1), 275-6.
  39. Grossman D, Rapini RP, Osborne B, Duvic (1994). Emergence of leprosy in a patient with mycosis fungoides. Journal of the American Academy of Dermatology, 30(2 Pt 2), 313-5.
  40. Grossman D, Heald PW, Wang C, Rinder H (1997). Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal of the American Academy of Dermatology, 37(3 Pt 1), 409-13.
  41. Alexander A, Harris RM, Grossman D, Bruggers CS, Leachman S (2004). Vulvar melanoma: diffuse melanosis and metastasis to the placenta. Journal of the American Academy of Dermatology, 50(2), 293-8.
  42. Goodson AG, Grossman (2009). Strategies for early melanoma detection: Approaches to the patient with nevi. Journal of the American Academy of Dermatology, 60(5), 719-35; quiz 736-8.
  43. Goodson AG, Florell SR, Boucher KM, Grossman (2010). Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. Journal of the American Academy of Dermatology, 62(4), 591-6.
  44. Duffy K, Grossman (2012). The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. Journal of the American Academy of Dermatology, 67(1), 1.e1-16; quiz 17-8.
  45. Duffy K, Grossman (2012). The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. Journal of the American Academy of Dermatology, 67(1), 19.e1-12; quiz 31-2.
  46. Soltani-Arabshahi R, Sweeney C, Jones B, Florell SR, Hu N, Grossman (2015). Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule. Journal of the American Academy of Dermatology, 72(3), 412-8.
  47. March J, Hand M, Grossman (2015). Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches. Journal of the American Academy of Dermatology, 72(6), 929-41; quiz 941-2.
  48. Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman (2016). Reduction in nevus biopsies in patients monitored by total body photography. Journal of the American Academy of Dermatology, 75(1), 135-143.e5.
  49. Nelson KC, Grossman D, Kim CC, Chen SC, Curiel-Lewandrowski CN, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming M (2018). Management strategies of academic pigmented lesion clinic directors in the United States. Journal of the American Academy of Dermatology, 79(2), 367-369.
  50. Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright L (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). Journal of the American Academy of Dermatology, 79(2), 238-244.
  51. Florell SR: Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA (2008). Sampling of melanocytic nevi for research purposes: A prospective study to determine effect on diagnosis. Journal of the American Academy of Dermatology, 59, 814-821.
  52. Klapperich ME, Bowen GM, Grossman (2019). Current controversies in early-stage melanoma: Questions on management and surveillance. Journal of the American Academy of Dermatology, 80(1), 15-25.
  53. Gardner LJ, Strunck JL, Wu YP, Grossman (2019). Current controversies in early-stage melanoma: Questions on incidence, screening, and histologic regression. Journal of the American Academy of Dermatology, 80(1), 1-12.
  54. Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob A (2020). A retrospective multicenter study of fatal pediatric melanoma. Journal of the American Academy of Dermatology, 83(5), 1274-1281.
  55. Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling T (2021). Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal of the American Academy of Dermatology, 84(4), 1164-1166.
  56. Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman (2005). Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. Journal of cutaneous pathology, 32(1), 45-9.
  57. Florell SR, Thomas J, Grossman (2007). Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. Journal of cutaneous pathology, 34(9), 667-74.
  58. Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman (2020). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. The Journal of dermatology, 47(4), 342-347.
  59. Grossman D, Cook RG, Sparrow JT, Mollick JA, Rich R (1990). Dissociation of the stimulatory activities of staphylococcal enterotoxins for T cells and monocytes. The Journal of experimental medicine, 172(6), 1831-41.
  60. Mollick JA, McMasters RL, Grossman D, Rich R (1993). Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity. The Journal of experimental medicine, 177(2), 283-93.
  61. Grossman D, Van M, Mollick JA, Highlander SK, Rich R (1991). Mutation of the disulfide loop in staphylococcal enterotoxin A. Consequences for T cell recognition. Journal of immunology (Baltimore, Md., 147(10), 3274-81.
  62. Grossman D, McNiff JM, Li F, Altieri D (1999). Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. The Journal of investigative dermatology, 113(6), 1076-81.
  63. Diedrich MJ, Warters RL, Grossman (2002). Amifostine aminothiols and protection of keratinocyte apoptosis and DNA damage. The Journal of investigative dermatology, 119(3), 707-8.
  64. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman (2003). Apoptosis regulators and responses in human melanocytic and keratinocytic cells. The Journal of investigative dermatology, 120(1), 48-55.
  65. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, Leachman S (2005). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. The Journal of investigative dermatology, 125(6), 1310-2.
  66. Raj D, Brash DE, Grossman (2006). Keratinocyte apoptosis in epidermal development and disease. The Journal of investigative dermatology, 126(2), 243-57.
  67. Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA, Grossman (2006). Activation of dual apoptotic pathways in human melanocytes and protection by survivin. The Journal of investigative dermatology, 126(10), 2247-56.
  68. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman S (2008). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. The Journal of investigative dermatology, 128(8), 2122-5.
  69. Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman (2013). Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. The Journal of investigative dermatology, 133(4), 1043-51.
  70. Rahman H, Kumar D, Liu T, Okwundu N, Lum D, Florell SR, Burd CE, Boucher KM, VanBrocklin MW, Grossman (2021). Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. The Journal of investigative dermatology, 141(1), 132-141.e3.
  71. Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, Leachman S, Cannon-Albright L (2018). A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. Journal of the National Cancer Institute, 110(12), 1380-1385.
  72. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman S (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. Journal of clinical oncology, 21(11), 2179-86.
  73. Grossman D, McNiff JM, Li F, Altieri D (1999). Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Laboratory investigation; a journal of technical methods and pathology, 79(9), 1121-6.
  74. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones D (2004). Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Molecular pharmacology, 65(1), 18-27.
  75. Liu T, Brouha B, Grossman (2004). Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene, 23(1), 39-48.
  76. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman (2006). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene, 25(52), 6968-74.
  77. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74.
  78. Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman S (2018). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient education and counseling, 101(3), 452-459.
  79. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman S (2019). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. Pediatric dermatology, 36(3), 317-323.
  80. Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, Leachman S (2003). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. Pigment cell research, 16(6), 662-9.
  81. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri D (2000). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences of the United States of America, 97(24), 13103-7.
  82. Grossman D, Kim PJ, Schechner JS, Altieri D (2001). Inhibition of melanoma tumor growth in vivo by survivin targeting. Proceedings of the National Academy of Sciences of the United States of America, 98(2), 635-40.
  83. Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes R (2013). Sentinel lymph node biopsy for melanoma in pregnant women. Annals of surgical oncology, 20(2), 689-96.
  84. Fuller SR, Bowen GM, Tanner B, Florell SR, Grossman (2007). Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatologic surgery, 33(10), 1198-206; discussion 1205-6.
  85. Goodson AG, Florell SR, Hyde M, Bowen GM, Grossman (2010). Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatologic surgery, 36(7), 1087-98.
  86. Goodson AG, Florell SR, Boucher KM, Grossman (2011). A decade of melanomas: identification of factors associated with delayed detection in an academic group practice. Dermatologic surgery, 37(11), 1620-30.
  87. Grossman D, Bowen G (2013). Commentary: transecting melanomas: does it matter?. Dermatologic surgery, 39(4), 616-7.
  88. Grossman D, Bowen G (2018). Commentary on Impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. Dermatologic surgery, 44(4), 502-503.
  89. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, Leachman S, Samlowski WE, Grossman (2007). N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clinical cancer research, 13(19), 5952-8.
  90. Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman (2009). Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clinical cancer research, 15(23), 7434-40.
  91. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak K (2020). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psycho-oncology, 29(1), 148-155.
  92. Strunck JL, Florell SR, Grossman (2018). Capillary hemangioma associated with dermal atrophy masquerading as a deep fungal infection.LID - 13030/qt4109m7ds [pii]. Dermatology online journal, 24(3),
  93. Hyde MA, Grossman D, Wu YP, Buys S, Gren LH, Hashibe (2020). Vitamin D, melanoma risk, and tumor thickness in PLCO cancer screening trial patients. JAAPA, 33(6), 35-41.
  94. John KK, Jensen JD, King AJ, Ratcliff CL, Grossman (2017). Do Pattern-Focused Visuals Improve Skin Self-Examination Performance? Explicating the Visual Skill Acquisition Model. Journal of health communication, 22(9), 732-742.
  95. Liu J, Dai Q, Chen J, Durrant D, Freeman A, Liu T, Grossman D, Lee R (2003). Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Molecular cancer research, 1(12), 892-902.
  96. Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest A (2021). Low accuracy of self-reported family history of melanoma in high-risk patients. Familial cancer, 20(1), 41-48.
  97. Jensen JD, Pokharel M, King AJ, John KK, Wu YP, Grossman (2020). Obstacles to skin self-examination: are frontier adults inclined abstainers?. Psychology, health & medicine, 25(4), 470-479.
  98. Li C, Liu T, Liu B, Hernandez R, Facelli JC, Grossman (2019). A novel CDKN2A variant (p16L117P ) in a patient with familial and multiple primary melanomas. Pigment cell & melanoma research, 32(5), 734-738.
  99. Casey MJ, Modzelewska K, Anderson D, Goodman J, Boer EF, Jimenez L, Grossman D, Stewart R (2017). A zebrafish brain tumor transplantation method for the long-term study of tumor cell behavior and drug response. Journal of visualized experiments, 123, e55712.
  100. Goodman JR, Grossman (2014). Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer prevention research (Philadelphia, Pa.), 7(6), 557-64.
  101. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman (2017). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer prevention research (Philadelphia, Pa.), 10(1), 36-44.
  102. Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman (2018). Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo. Cancer prevention research (Philadelphia, Pa.), 11(10), 629-642.
  103. Okwundu N, Rahman H, Liu T, Florell SR, Boucher KM, Grossman (2021). A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage. Cancer prevention research (Philadelphia, Pa.), 15, 129-138.
  104. King AJ, Gehl RW, Grossman D, Jensen J (2013). Skin self-examinations and visual identification of atypical nevi: comparing individual and crowdsourcing approaches. Cancer epidemiology, 37(6), 979-84.
  105. Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, Leachman S (2013). Selenium for the prevention of cutaneous melanoma. Nutrients, 5(3), 725-49.
  106. Varedi A, Rahman H, Kumar D, Catrow JL, Cox JE, Liu T, Florell SR, Boucher KM, Okwundu N, Burnett WJ, VanBrocklin MW, Grossman (2020). ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals (Basel, Switzerland), 13(1),
  107. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong H (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399.
  108. Tyagi E, Liu B, Li C, Liu T, Rutter J, Grossman (2017). Loss of p16INK4A stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. Oncotarget, 8(34), 55848-55862.
  109. McNeal AS, Belote RL, Zeng H, Urquijo M, Barker K, Torres R, Curtin M, Shain AH, Andtbacka RH, Holmen S, Lum DH, McCalmont TH, VanBrocklin MW, Grossman D, Wei ML, Lang UE, Judson-Torres R (2021). BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB. eLife, 10,
  110. Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC, Pigmented Lesion Subcommittee, Melanoma Prevention Working Group (2018). Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. JAMA dermatology, 154(12), 1401-1408.
  111. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter S (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA dermatology, 156(9), 1004-1011.
  112. Jenkins NC, Grossman (2013). Role of melanin in melanocyte dysregulation of reactive oxygen species. BioMed research international, 2013, 908797.
  113. Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami (2021). The dark side of immunotherapy. Annals of translational medicine, 9(12), 1041.
  114. Parsons BG, Nagelhout ES, Wankier AP, Hu N, Lensink R, Zhu A, Nottingham K, Grossman D, Jensen JD, Wu Y (2021). Reactivity to UV Radiation Exposure Monitoring Using Personal Exposure Devices for Skin Cancer Prevention: Longitudinal Observational Study. JMIR mHealth and uHealth, 9(9), e29694.
  115. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong M (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma management, 4(1), 13-37.
  116. Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, Leachman SA, Swetter S (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma management, 6(4), MMT32.
  117. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong H (2016). Intratumoral ipilimumab and interleukin-2 produce high rates of abscopal responses with low toxicity in patients with advanced melanoma. JAMA oncology, 7(39), 64390-99.
  118. Luo X, Zhou Y, Smart T, Grossman D, Sanchez (2021). Electrical Characterization of Basal Cell Carcinoma Using a Handheld Electrical Impedance Dermography Device. JID innovations, 2(1), 100075.
  119. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899.
  120. Elkeeb DM, Hopkins ZH, Bolender CM, Moreno C, Florell SR, Bowen AR, Vitale P, Zussman J, Duffy K, Grossman D, Secrest AM, Wada D (2023). A Single-Institution Cohort Study With Nevi of Special Site: Recurrence, Progression to Melanoma, and Patterns of Management. The American Journal of dermatopathology, 45(1), 28-39.
  121. Rahman H, Liu T, Askaryar S, Grossman (2023). Aspirin Protects against UVB-Induced DNA Damage through Activation of AMP Kinase. The Journal of investigative dermatology, 143(1), 154-162.e3.
  122. Brady HL, Hamilton JG, Kaphingst KA, Jensen JD, Kohlmann W, Parsons BG, Lillie HM, Wankier AP, Smith HJ, Grossman D, Hay JL, Wu Y (2022). 'I had a bigger cancer risk than I thought¿': The experience of receiving personalized risk information as part of a skin cancer prevention intervention in the college setting. Health expectations, 25(6), 2937-2949.
  123. Wu YP, Hamilton JG, Kaphingst KA, Jensen JD, Kohlmann W, Parsons BG, Lillie HM, Wang X, Haaland B, Wankier AP, Grossman D, Hay J (2022). Increasing Skin Cancer Prevention in Young Adults: the Cumulative Impact of Personalized UV Photography and MC1R Genetic Testing. Journal of cancer education, 38(3), 1059-1065.
  124. Wu YP, Parsons B, Jo Y, Chipman J, Haaland B, Nagelhout ES, Carrington J, Wankier AP, Brady H, Grossman (2022). Outdoor activities and sunburn among urban and rural families in a Western region of the US: Implications for skin cancer prevention. Preventive medicine reports, 29, 101914.
  125. Wu YP, Stump TK, Hay JL, Aspinwall LG, Boucher KM, Deboeck PR, Grossman D, Mooney K, Leachman SA, Smith KR, Wankier AP, Brady HL, Hancock SE, Parsons BG, Tercyak K (2023). The Family Lifestyles, Actions and Risk Education (FLARE) study: Protocol for a randomized controlled trial of a sun protection intervention for children of melanoma survivors. Contemporary clinical trials, 131, 107276.
  126. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950.
  127. Trepanowski N, Chang MS, Zhou G, Ahmad M, Berry EG, Bui K, Butler WH, Chu EY, Curiel-Lewandrowski C, Dellalana LE, Ellis DL, Freeman SC, Gorrepati PL, Grossman D, Gyurdzhyan S, Kanetsky PA, King ALO, Kolla AM, Lian CG, Lin JY, Liu V, Lowenthal A, McCoy KN, Munjal A, Myrdal CN, Perkins S, Powers JG, Rauck C, Smart TC, Stein JA, Venna S, Walsh ME, Wang JY, Leachman SA, Swetter SM, Hartman R (2022). Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study. Journal of the American Academy of Dermatology, 87(5), 1217-1219.

Review

  1. Pho L, Grossman D, Leachman SA (2006). Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. [Review]. Curr Opin Oncol, 18, (2), 173-9.
  2. Brash DE, Zhang W, Grossman D, Takeuchi S (2005). Colonization of adjacent stem cell compartments by mutant keratinocytes. [Review]. Semin Cancer Biol, 15, (2), 97-102.
  3. March J, Hand M, Truong A, Grossman (2015). Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. Journal of the American Academy of Dermatology, 72(6), 943-58; quiz 959-60.
  4. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clinical cancer research, 27(10), 2678-2697.
  5. Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen S (2015). Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA dermatology, 151(2), 212-8.
  6. Hand M, Chien A, Grossman (2015). Screening and non-invasive evaluative devices for melanoma detection: a comparison of commercially available devices and dermoscopic evaluation. 2, 005.

Book Chapter

  1. Grossman D, Leffell D (2008). Squamous cell carcinoma.
  2. Cassidy PB, Leachman SA, Grossman (2012). N-acetylcysteine for Reduction of Oxidative Stress-Damage and Prevention of Melanoma.
  3. Grossman D, Leffell D (1999). The clinical biology and molecular basis of squamous cell carcinoma.
  4. Grossman D, Leffell D (2003). Squamous cell carcinoma.
  5. Cassidy PB, Grossman D, Leachman S (2012). Melanoma Prevention. 30-42.
  6. Grossman D, Leffell D (2012). Squamous cell carcinoma.

Conference Proceedings

  1. Leachman SA, Smalley KSM, Grossman D, Bowen GM, Messina JL, Berwick M, Glass LF, Swetter SM, Sondak (2012). Joint melanoma meetings in Tampa enhance communication and collaboration. 7, 129-131.

Commentary

  1. Grossman D (2011). Failure to compare dermoscopy findings of pigmented lesions on your patient: Comment on "Dermoscopy of patients with multiple nevi". Arch Dermatol, 147(1), 50.
  2. Grossman D, Duvic (1995). Reply to response to "Idiopathic CD4 T-lymphocytopenia in a patient with mycosis fungoides". Journal of the American Academy of Dermatology, 32, 1064.
  3. Grossman (2004). Imatinib mesylate for melanoma: will a new target be revealed?. The Journal of investigative dermatology, 123(6), xi-xiii.
  4. Cotter MA, Florell SR, Leachman SA, Grossman (2008). Reply to responses to "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". The Journal of investigative dermatology, 128, 1583-1584.
  5. Grossman D, Bowen G (2018). Commentary on impact of National Comprehensive Cancer Network Guidelines on Case Selection and Outcomes for Sentinel Lymph Node Biopsy in Thin Melanoma. Dermatologic surgery, (44), 502-503.
  6. Kim CC, Swetter S, Curiel-Lewandrowski, Grichnik J, Grossman D, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen (2015). Complete excision of atypical/dysplastic nevi: Addressing the gap in clinical practice recommendations and need for more data to guide management. Pigmented Lesion Subcommittee consensus statement. JAMA dermatology, 151(2), 212-218.

Case Report

  1. Shah A, Hyngstrom J, Florell SR, Grossman (2019). Use of the Pigmented Lesion Assay to rapidly screen a patient with numerous clinically atypical pigmented lesions. JAAD case reports, 5(12), 1048-1050.

Editorial

  1. Varedi A, Wu YP, Klein SZ, Leachman SA, Grossman (2019). Mineral sunscreens not recommended by Consumer Reports: Suggestions to improve the review process. Journal of the American Academy of Dermatology, 80(3), 832-833.

Letter

  1. McGovern TW, Grossman D, Fitzgerald D, Glusac EJ, Leffell D (1999). Status of residual tumor in patients with squamous cell carcinoma referred for Mohs micrographic surgery. [Letter to the editor]. Arch Dermatol, 135(12), 1557-9.
  2. Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman (2019). Powering a prospective melanoma chemoprevention trial in high-risk cohorts. International journal of dermatology, 58(11), e232-e234.
  3. Grossman D, Duffy KL, Bowen G (2012). Surgical margins for melanoma in situ. Journal of the American Academy of Dermatology, 67(5), 1068-9; author reply 1069-71.
  4. Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman (2014). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. Journal of the American Academy of Dermatology, 71(4), 835-8.
  5. Varedi A, Gardner LJ, Kim CC, Chu EY, Ming ME, Leachman SA, Curiel-Lewandrowski C, Swetter SM, Grossman (2020). Use of new molecular tests for melanoma by pigmented-lesion experts. Journal of the American Academy of Dermatology, 82(1), 245-247.
  6. Grossman D, Florell SR, Duffy KL, Bowen G (2020). Histologic criteria for assessing surgical margins in melanoma in situ. Journal of the American Academy of Dermatology, 82(4), e133-e134.
  7. Cotter MA, Florell SR, Leachman SA, Grossman (2007). Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. The Journal of investigative dermatology, 127(10), 2469-71.
  8. Grossman D, Duvic (1993). Cutaneous T-cell lymphoma after blood transfusion. Lancet (London, England), 342(8885), 1483.
  9. Duvic M, Grossman (1994). More on acyclovir for chickenpox. The New England journal of medicine, 331(1), 59.
  10. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri D (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. The New England journal of medicine, 341(6), 452-3.
  11. Grossman D, Sweeney C, Doherty J (2021). The Rapid Rise in Cutaneous Melanoma Diagnoses. The New England journal of medicine, 384(14), e54.
  12. Chang MS, Leachman SA, Berry EG, Curiel-Lewandrowski C, Geller AC, Grossman D, Kim CC, Stein JA, Swetter SM, Hartman R (2021). Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey. Dermatology online journal, 27(4),

Other

  1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients.

Research Lab

Lab link

News & Podcasts

News

Huntsman Cancer Institute News

Podcasts